Clinical Trial Update: Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial of docetaxel (Taxotere), cisplatin, and 5-fluorouracil for gastric or gastroesophageal junction adenocarcinoma; no results or status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: McGill University | Conditions: Gastric Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN